Myasthenia gravis induced in mice by immunization with the recombinant extracellular domain of rat muscle-specific kinase (MuSK)

Journal of Neuroimmunology

Volumn 175, Issue 1-2, 2006, Pages 107-117

  Jha, Smita ^a   Xu, Kaiping ^a   Maruta, Takahiro ^b   Oshima, Minako ^b   Mosier, Dennis R ^b,c   Atassi, M Zouhair ^b   Hoch, Werner ^a  

^a University of Houston   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Agrin; Antibodies; Autoimmunity; Mouse model; Muscle specific kinase; Myasthenia gravis

Indexed keywords

AGRIN; CHOLINERGIC RECEPTOR ANTIBODY; MUSCLE SPECIFIC KINASE; PHOSPHOTRANSFERASE; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOIMMUNITY; CHO CELL; CONTROLLED STUDY; DISEASE MODEL; ELECTROPHYSIOLOGY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME PURIFICATION; IMMUNE RESPONSE; IMMUNIZATION; MOUSE; MUSCLE ACTION POTENTIAL; MUSCLE WEAKNESS; MYASTHENIA GRAVIS; NERVE STIMULATION; NONHUMAN; PRIORITY JOURNAL; STATISTICAL ANALYSIS; TREMOR; WEIGHT REDUCTION;

ACTION POTENTIALS; ANIMALS; AUTOANTIBODIES; CELLS, CULTURED; CRICETINAE; EXTRACELLULAR FLUID; FEMALE; IMMUNIZATION; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, TRANSGENIC; MUSCLE, SKELETAL; MYASTHENIA GRAVIS; PROTEIN STRUCTURE, TERTIARY; RATS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTORS, CHOLINERGIC; RECOMBINANT PROTEINS;

EID: 33646780233     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2006.03.016     Document Type: Article

References (46)

1. Agius M.A., Richman D.P., Fairclough R.H., Aarli J., Gilhus N.E., and Romi F. Three forms of immune myasthenia. Ann. N.Y. Acad. Sci. 998 (2003) 453-456
2. Atassi M.Z. Molecular recognition of acetylcholine receptor. Recognition by α-neurotoxins and by immune and autoimmune responses and manipulation of the responses. Adv. Neuroimmunol. 4 (1995) 403-432
3. Atassi M.Z., and Oshima M. Autoimmune responses against acetylcholine receptor: T and B cell collaboration and manipulation by synthetic peptides. Crit. Rev. Immunol. 17 (1997) 481-495
4. Atassi M.Z., Ruan K.H., Jinnai K., Oshima M., and Ashizawa T. Epitope-specific suppression of antibody response in experimental autoimmune myasthenia gravis by an mPEG conjugate of a myasthenogenic synthetic peptide. Proc. Natl. Acad. Sci. U. S. A. 89 (1992) 5852-5856
5. Atassi M.Z., Oshima M., and Deitiker P. On the initial trigger of myasthenia gravis and suppression of the disease by antibodies against MHC peptide region involved in the presentation of a pathogenic T cell epitope. Crit. Rev. Immunol. 21 (2001) 1-27
6. Baggi F., Andreetta F., Antozzi C., Simoncini O., Confalonieri P., Labeit S., Cornelio F., and Mantegazza R. Anti-titin and antiryanodine receptor antibodies in myasthenia gravis patients with thymoma. Ann. N.Y. Acad. Sci. 841 (1998) 538-541
7. Berman P.W., and Patrick J. Linkage between the frequency of muscular weakness and loci that regulate immune responsiveness in murine experimental autoimmune myasthenia gravis. J. Exp. Med. 152 (1980) 507-520
8. Besser J., Zahalka M.A., and Ullrich A. Exclusive expression of the receptor tyrosine kinase MDK4 in skeletal muscle and the decidua. Mech. Dev. 59 (1996) 41-52
9. Chevessier F., Faraut B., Ravel-Chapuis A., Richard P., Gaudon K., Bauche S., Prioleau C., Herbst R., Goillot E., Ioos C., Azulay J., Attarian S., Leroy L., Fournier E., Legay C., Schaeffer L., Koenig J., Fardeau M., Eymard B., Pouget J., and Hantai D. MuSK, a new target for mutations causing congenital myasthenic syndrome. Hum. Mol. Genet. 24 (2004) 3229-3240
10. Christadoss P., Krco C.J., Lennon V.A., and David C.S. Genetic control of experimental autoimmune myasthenia gravis in mice. II. Lymphocyte proliferative response to acetylcholine receptor is dependent on Lyt-1 + 23- cells. J. Immunol. 126 (1981) 1646-1647
11. Christadoss P., Lennon V.A., Krco C.J., and David C.S. Genetic control of experimental autoimmune myasthenia gravis in mice. III. Ia molecules mediate cellular immune responsiveness to acetylcholine receptors. J. Immunol. 128 (1982) 1141-1144
12. DeChiara T.M., Bowen D.C., Valenzuela D.M., Simmons M.V., Poueymirou W.T., Thomas S., Kinetz E., Compton D.L., Rojas E., Park J.S., Smith C., DiStefano P.S., Glass D.J., Burden S.J., and Yancopoulos G.D. The receptor tyrosine kinase MuSK is required for neuromuscular junction formation in vivo. Cell 85 (1996) 501-512
13. Evoli A., Tonali P.A., Padua L., Monaco M.L., Scuderi F., Batocchi A.P., Marino M., and Bartoccioni E. Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis. Brain 126 (2003) 2304-2311
14. Giraud M., Beaurain G., Yamamoto A.M., Eymard B., Tranchant C., Gajdos P., and Garchon H.J. Linkage of HLA to myasthenia gravis and genetic heterogeneity depending on anti-titin antibodies. Neurology 57 (2001) 1555-1560
15. Giraud M., Eymard B., Tranchant C., Gajdos P., and Garchon H.J. Association of the gene encoding the delta-subunit of the muscle acetylcholine receptor (CHRND) with acquired autoimmune myasthenia gravis. Genes Immun. 5 (2004) 80-83
16. Herbst R., Avetisova E., and Burden S.J. Restoration of synapse formation in Musk mutant mice expressing a Musk/Trk chimeric receptor. Development 129 (2002) 5449-5460
17. Hesser B.A., Sander A., and Witzemann V. Identification and characterization of a novel splice variant of MuSK. FEBS Lett. 442 (1999) 133-137
18. Hoch W. Formation of the neuromuscular junction: agrin and its unusual receptors. Eur. J. Biochem. 265 (1999) 1-10
19. Hoch W., Campanelli J.T., Harrison S., and Scheller R.H. Structural domains of agrin required for clustering of nicotinic acetylcholine receptors. EMBO J. 13 (1994) 2814-2821
20. Hoch W., McConville J., Helms S., Newsom-Davis J., Melms A., and Vincent A. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat. Med. 7 (2001) 365-368
21. Hopf C., and Hoch W. Heparin inhibits actylcholine receptor aggregation at two distinct steps in the agrin-induced pathway. Eur. J. Neurosci. 9 (1997) 1170-1177
22. Hopf C., and Hoch W. Dimerization of the muscle-specific kinase induces tyrosine phosphorylation of acetylcholine receptors and their aggregation on the surface of myotubes. J. Biol. Chem. 273 (1998) 6467-6473
23. Hopf C., and Hoch W. Tyrosine phosphorylation of the muscle specific kinase (MuSK) is exclusively induced by AChR-aggregating agrin fragments. Eur. J. Biochem. 253 (1998) 382-389
24. Kong X., Barzaghi P., and Ruegg M. Inhibition of synapse assembly in mammalian muscle in vivo by RNA interference. EMBO Rep. 5 (2004) 1-6
25. Lin W., Dominguez B., Yang J., Aryal P., Brandon E.P., Gage F.H., and Lee K.F. Neurotransmitter acetylcholine negatively regulates neuromuscular synapse formation by a Cdk5-dependant mechanism. Neuron 46 (2005) 569-579
26. Lindstrom J. Is "seronegative" MG explained by autoantibodies to MuSK?. Neurology 62 (2004) 1920-1921
27. Marx A., Wilisch A., Schultz A., Greiner A., Magi B., Pallini V., Schalke B., Toyka K., Nix W., Kirchner T., and Muller-Hermelink H.K. Expression of neurofilaments and of a titin epitope in thymic epithelial tumors. Implications for the pathogenesis of myasthenia gravis. Am. J. Pathol. 148 (1996) 1839-1850
28. Mosier D.R., Siklós L., and Appel S.H. Resistance of extraocular motoneuron terminals to effects of amyotrophic lateral sclerosis sera. Neurology 54 (2000) 252-255
29. Nakayashiki N., Oshima M., Deitiker P., Ashizawa T., and Atassi M.Z. Suppression of experimental myasthenia gravis by monoclonal antibodies against MHC peptide region involved in presentation of a pathogenic T cell epitope. J. Neuroimmunol. 105 (2000) 131-144
30. Nemoto Y., Kuwabara S., Misawa S., Kuwaguchi T., Hattori T., Takamori M., and Vincent A. Patterns and severity of neuromuscular transmission failure in seronegative myasthenia gravis. J. Neurol. Neurosurg. Psychiatry 76 (2005) 714-718
31. Oshima M., and Atassi M.Z. T cells of mice treated with mPEG-myasthenogenic peptide conjugate are involved in protection against EAMG by stimulating lower pathogenic antibody responses. Autoimmunity 32 (2000) 45-55
32. Oshima M., Ashizawa T., Pollack M.S., and Atassi M.Z. Autoimmune T-cell recognition of human acetylcholine receptor: the sites of T-cell recognition in myasthenia gravis on the extracellular part of the α-subunit. Eur. J. Immunol. 20 (1990) 2563-2569
33. Patrick J., and Lindstrom J. Autoimmune response to acetylcholine receptor. Science 180 (1973) 871-872
34. Rosenberg J., Oshima M., and Atassi M.Z. B-cell activation in vitro by helper T cells specific to region α 146-162 of Torpedo californica acetylcholine receptor. J. Immunol. 157 (1996) 3192-3299
35. Sander A., Hesser B., and Witzemann V. MuSK induces in vivo acetylcholine receptor clusters in a ligand-independant manner. J. Cell Biol. 155 (2001) 1287-1296
36. Sanders D., El-Salem K., Massey J., McConville J., and Vincent A. Clinical aspects of MuSK-antibody positive seronegative MG. Neurology 60 (2003) 1978-1980
37. Sanes J.R., and Lichtman J. Induction, assembly, maturation and maintenance of a postsynaptic apparatus. Nat. Rev., Neurosci. 2 (2001) 1287-1296
38. Scuderi F., Marino M., Colonna L., Mannella F., Evoli A., Provenzano C., and Bartoccioni E. Anti-p110 autoantibodies identify a subtype of "seronegative" myasthenia gravis with prominent oculobulbar involvement. Lab. Invest. 82 (2002) 1139-1146
39. Selcen D., Fukuda T., Shen X.-M., and Engel A. Are MuSK antibodies the primary cause of myathenic symptoms?. Neurology 62 (2004) 1945-1950
40. Shenoy M., Oshima M., Atassi M.Z., and Christadoss P. Suppression of experimental autoimmune myasthenia gravis by epitope-specific neonatal tolerance to synthetic region α 146-162 of acetylcholine receptor. Clin. Immunol. Immunopathol. 66 (1993) 230-238
41. Shiraishi H., Motomura M., Yoshimura T., Fukudome T., Fukuda T., Nakao Y., Tsujihata M., Vincent A., and Eguchi K. Acetylcholine receptors loss and postsynaptic damage in MuSK antibody-positive myasthenia gravis. Ann. Neurol. 57 (2005) 289-293
42. Valenzuela D.M., Stitt T.N., DiStefano P.S., Rojas E., Mattsson K., Compton D.L., Nunez L., Park J.S., Stark J.L., Gies D.R., Thomas S., Le Beau M.M., Fernald A.A., Copeland N.G., Jenkins N.A., Burden S.J., Glass D.J., and Yancopoulos G.D. Receptor tyrosine kinase specific for the skeletal muscle lineage: expression in embryonic muscle, at the neuromuscular junction, and after injury. Neuron 15 (1995) 573-584
43. Vincent A., Bowen J., Newsom-Davis J., and McConville J. Seronegative generalised myasthenia gravis: clinical features, antibodies, and their targets. Lancet 2 (2003) 99-106
44. Yamamoto A.M., Gajdos P., Eymard B., Tranchant C., Warter J.M., Gomez L., Bourquin C., Bach J.F., and Garchon H.J. Anti-titin antibodies in myasthenia gravis: tight association with thymoma and heterogeneity of nonthymoma patients. Arch. Neurol. 58 (2001) 885-890
45. Yokoi T., Mulac-Jericevic B., Kurisaki J., and Atassi M.Z. T lymphocyte recognition of acetylcholine receptor: localization of the full T-cell recognition profile on the extracellular part of the α chain of Torpedo californica acetylcholine receptor. Eur. J. Immunol. 17 (1987) 1697-1702
46. Zhou L., McConville J., Chaudhry V., Adams R., Skolasky M., Vincent A., and Drachman D. Clinical comparison of muscle-specific kinase (MuSK) antibody-positive and -negative myasthenia gravis patients. Muscle Nerve 30 (2004) 55-60